Pharmaceutical companies in India are expected to grow steadily at a rate of approximately 10 per cent in FY26, driven by price increases and the launch of new products, according to a report by ICICI Securities.
The Indian pharmaceutical market maintained its growth trajectory in April 2025 with a robust 7.8 per cent increase year-over-year growth, translating into an incremental Rs 1,424 Crore sales, according to a report by Pharmatrack.
Dr Huzaifa Khorakiwala, Executive Director of Wockhardt Limited, on Saturday said that the fall of US reciprocal tariffs on Indian pharmaceutical products will pose a significant challenge to the industry.
Indian pharma companies like CDMOs (Contract Development and Manufacturing Organizations) will not see major disruptions from the proposed US tariffs of 10-25 per cent, according to a report by B&K Securities.
India's pharmaceutical industry is poised for significant growth, with its share in the global market expected to rise to 5 per cent by 2030, according to a report by Bain & Company.
Strong pricing growth (+5.3 per cent YoY) and the launch of new products from recent patent expiries (+2.6 per cent YoY) have continued to drive overall market performance.
The report says companies within the coverage are anticipated to post a collective revenue growth of 8.5 per cent year-on-year (YoY) and 3.1 per cent quarter-on-quarter (QoQ) for the second quarter of FY25.
India's pharmaceutical industry is facing a serious threat due to the increasing import of substandard Isopropyl Alcohol (IPA) and non-pharmacopoeia grade IPA from China, according to industry experts.
The demand for generic medicines in India is rising rapidly, while the sales of branded drugs are seeing a decline in sales, indicates a recent report by UBS.
Panchkula (Haryana) [India], September 27: Key leaders from Panchkula's pharmaceutical sector gathered today at Mits Healthcare to advocate for Special Economic Zone (SEZ) status for the region, a move they believe will catalyze growth and attract substantial investments into the pharma indu
Kenya [East Africa], August 29: As part of Kenya's Big 4 Agenda, local manufacturing stands as a crucial pillar for achieving sustainable economic growth. This vision is being actualized through initiatives that promote self-reliance and reduce dependency on imports. A shining example of thi